Bolt Biotherapeutics, Inc. — Form 8-K
Filed October 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 45/100
What the filing says
Bolt Biotherapeutics filed an 8-K on October 6, 2026, reporting entry into a Material Definitive Agreement effective October 1, 2026 (Item 1.01). The filing document itself contains no details on counterparties, dollar amounts, percentages, share counts, or the nature of the agreement—only that such an agreement was executed.
Why this rating
Material agreement announced but no terms disclosed in filing text; cannot assess magnitude. Company scale ~$7.3M; materiality depends on undisclosed deal size.
Extracted items
See more from October 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.